HelpHelp About Us Contact Contact Us Help Help
Press Release Service
user name password
Client login:   
First time user sign up Forgot your login info?
Website Directory     Submit Website

Search
EmailWire News Links

Home > News By Company > Ultroid Technologies, Inc.

Print e mail rss del Y! myWeb Tweet
 

ULTROID TECHNOLOGIES NAMES NEW MEDICAL DIRECTOR

ST PETERSBURG, FLORIDA, MAY 21, 2009 Dr. Allison Karolak has been named Medical Director of Ultroid Technologies, Inc., the fastest growing medical device Company in the US, and its parent company, Vascular Technologies Inc., that owns Ultroid and also o

(EMAILWIRE.COM, May 21, 2009 ) ST PETERSBURG, FLORIDA, MAY 21, 2009

 Dr. Karolak appointed new medical director
 Board Certified Family Physician provides her expertise
 Views Ultroid as a win-win-win-win situation

- In Good Company

Dr. Karolak represents the latest addition to our Ultroid team of professionals. She brings a unique perspective to our company as both a physician and a patient. Dr. Karolak is, and will always remain, a patient advocate. As a family physician, she touched the lives of many with her profound caring and exceptional clinical skills but felt compelled to bring relief to patients on a national scale. Dr. Karolak is passionate about her quest to assist in relieving millions of patients from the burden of hemorrhoidal disease. As a mother of two small children, she suffered silently for years without treatment of internal hemorrhoids due to the lack of desirable treatment options. Then, Dr. Karolak discovered Ultroid. It changed her life and ignited a desire and sense of responsibility to get the word out to both physicians and patients that finally there is an effective, painless treatment for internal hemorrhoids.
Dr. Karolak is a proud graduate of the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine. She deeply believes in the principle of treating each and every patient with a holistic approach, understanding that not only are they affected physically by their illnesses but psychologically and socially as well. Dr. Karolak completed her internship at Union Hospital, an affiliate of the Saint Barnabas Health System and her Family Medicine residency at Christ Hospital in Jersey City, New Jersey. She is board certified in Family Practice and Osteopathic Manipulative Treatment. Dr. Karolak is a proud member of the American Osteopathic Association and the American College of Osteopathic Family Physicians.

- Positive Outlook

“It is a win-win-win-win situation, really no one loses,” declares Dr. Karolak, “The patient gets a painless treatment, the doctor has an attractive treatment option, he gets paid, and it’s cheaper than the other modalities for the insurance companies. I was fascinated for several reasons.”

- Vision and Agenda

Dr. Karolak shares her vision and agenda, “My top three priorities are clinical research, training for everyone who touches Ultroid and awareness of our product for both doctors and patients.” Karolak details her plan, “It is my goal to recruit physicians across the country to participate in randomized, multi-center, prospective studies comparing Ultroid with the other treatment modalities.” Dr. Karolak plans on educating within the company as well, “I will be working with our staff at every level and with our distributors and their representatives, to educate them with the facts about our product. I plan to design and implement training manuals for each department of our company with the facts about Ultroid that are applicable to their job.”

- Changing Medicine

“We believe that through education,” explains Dr. Karolak, “we can change the public’s perception of hemorrhoids as a taboo subject that affects individuals in the privacy of their bathrooms in to a disease that affects millions on a daily ongoing basis.” Dr. Karolak stresses, “It’s time to talk about it because now there is something to do about it. U2 can change your life!”

- About Vascular and Ultroid Technologies, Inc.

Vascular Technologies, Inc. is one of the fastest growing medical device companies in the United States. Its principal product is the Ultroid® Medical System, a non-invasive, pain-free, and lower cost treatment than current procedures for the treatment of Hemorrhoid Disease (HD) with further applications for the treatment of other varicose and spider veins. In over 40,000 procedures Ultroid® has had over a 95% effective rate with no reported complications, and replaces ineffective over-the-counter creams and painful surgeries that can be accompanied by infection and prolonged recovery. The Ultroid® procedure can be performed by any physician, regardless of specialty, in their office, in usually less than 10 minutes. Patients are able to resume their normal daily activities immediately, versus the several month recovery often associated with current laser and other surgical treatments. Ultroid® is the only FDA-cleared Medical Device for the treatment of all grades of Hemorrhoids and accepted by most insurers and Medicare.

The Company's website is www.Ultroid.com. The brand names referenced in this press release are trademarks of Vascular Technologies, Inc. and Ultroid® Technologies, Inc. its affiliated companies, customers, or other third parties. The company manages web video enabled training clinics, Ultroid Wellness Centers and markets and manufactures the Ultroid® Medical Device.

- Safe Harbor Statements

This press release may contain forward-looking statements reflecting management's current expectations regarding future results of operations, economic performance, financial condition and achievements of the Company. The forward-looking statements are based on the assumption that operating performance will continue to exponentially grow in line with recent trends and consistent with distribution expansion. Management believes these assumptions to be reasonable but there is no assurance that they will prove to be accurate. Forward-looking statements, specifically those concerning future performance are subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties are detailed from time to time in the Company's filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

Contact Information:
Ultroid Technologies, Inc.
Mike Wodstrchill
Tel: 877-858-0555
Email us


This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Press Release Keywords:

Device, Manufacturer, ISO, International, Investor, Hemorrhoid, HD, Pain-Free

Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International

Equityallianceir.com





Penny Stocks to Watch

Sign up for hot penny stock picks
Gains of 500%+ possible!

Premiumstockpicks.com/landing/




Satellite TV for PC

Watch Streaming Tv Right on Your PC

Satellitetelevisionforpc.com



 



Your text Ads & 

PR

Text Ads plus unlimited press releases, One release featured/Day for only $575 per month.

Read more on Text Ads & PR






Your text Ads Here!

Text Ads are only $289 per month. Ads are placed same day.

More on Text Ads Advertising




 

Search


Advertising | How to contact us | Privacy Statement | EmailWire Press Releases | Partnership Opportunities

EmailWire is a press release distribution service of GroupWeb Media LLC.

© Copyright GroupWeb Media LLC 2012